Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

QVAR RediHaler Inhalation Aerosol Approved

Teva Pharmaceutical news release; 2017 Aug 7

The FDA has approved QVAR RediHaler (beclomethasone dipropionate HFA) inhalation aerosol (Teva Pharmaceucials, Jerusalem), a maintenance treatment option designed to eliminate the need for hand-breath coordination during inhalation.

Indications: QVAR RediHaler is a corticosteroid indication for the maintenance treatment of asthma as prophylactic therapy in patients 4 years of age and older.

Dosage and administration: Breath-actuated inhalation aerosol: 40 or 80 mcg per actuation.

Adverse reactions: The most common adverse reactions (incidence ≥3% and >placebo) include oral candidiasis, upper respiratory tract infection, nasopharyngitis, allergic rhinitis, oropharyngeal pain, and sinusitis.

Citation:

Teva announces FDA approval of QVAR RediHaler (beclomethasone dipropionate HFA) inhalation aerosol. [news release]. Jerusalem; Teva Pharmaceutical Industrial Ltd.; August 7, 2017: http://www.tevapharm.com/news/teva_announces_fda_approval_of_qvar_rediha.... Accessed August 12, 2017.